test

Leukemia, Lymphoma, and Myeloma

10
A Multicenter Phase II Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma
Disease/Condition: Multiple Myeloma
Principal Investigator: Terri Parker
A Phase I Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Disease/Condition: Leukemia, not otherwise specified | Leukemia, other | Myeloid and Monocytic Leukemia
Principal Investigator: Steven Gore
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Female Genital | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Principal Investigator: Madhav Dhodapkar
A Phase II Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome
Disease/Condition: Mycosis Fungoides
Principal Investigator: Francine Foss
A Phase III Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for patients with High Allelic Ratio FLT3/ITD
Disease/Condition: Cancer | Myeloid and Monocytic Leukemia
Principal Investigator: Nina Kadan-Lottick
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Disease/Condition: Leukemia, other
Principal Investigator: Steven Gore
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Principal Investigator: Nina Kadan-Lottick
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Disease/Condition: Leukemia, other
Principal Investigator: Iris Isufi
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Disease/Condition: Hodgkin's Lymphoma
Principal Investigator: Nina Kadan-Lottick
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Disease/Condition: Lymphoid Leukemia
Principal Investigator: Iris Isufi
A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Steven Gore
A Randomized, Double-Blind Phase 1B/2 Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia
Disease/Condition: Leukemia, not otherwise specified | Leukemia, other | Myeloid and Monocytic Leukemia
Principal Investigator: Steven Gore
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Brentuximab Vedotin and CHP (A+CHP) versus CHOP in the Frontline Treatment of Patients with CD30- Positive Mature T-cell Lymphomas
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
AALL1231 -- A Phase III Randomized Trial Investigating Bortezomib (NSC#681239; IND#58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL_ and T-Lymphoblastic Lymphoma (T-LLy) -- A Groupwide Phase III Study
Principal Investigator: Nina Kadan-Lottick
An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Disease/Condition: Breast - Female | Lung | Ovary
Principal Investigator: Joseph Paul Eder
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial
Disease/Condition: Leukemia, other
Principal Investigator: Nina Kadan-Lottick
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Disease/Condition: Other Digestive Organ | Unknown Sites
Principal Investigator: Joseph Paul Eder
Newly Diagnosed High Risk B-Precursor ALL - Clofarabine
Disease/Condition: Leukemia, not otherwise specified
Principal Investigator: Nina Kadan-Lottick
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss